Oliveto Joseph 4
4 · Milestone Pharmaceuticals Inc. · Filed Apr 20, 2026
Research Summary
AI-generated summary of this filing
Milestone (MIST) CEO Joseph Oliveto Sells 36,500 Shares
What Happened
Joseph Oliveto, President, CEO and Director of Milestone Pharmaceuticals (MIST), reported the sale of 36,500 shares on April 16, 2026. The shares were disposed of at a weighted average price of $2.26 per share for total proceeds of approximately $82,490. The filing lists the transaction as an open-market or private sale (code S).
Key Details
- Transaction date: 2026-04-16 (reported on Form 4 filed 2026-04-20; filing is within the 2-business-day window)
- Price: weighted average $2.26; individual sale prices ranged from $2.25 to $2.28 (footnote indicates multiple trades within that range)
- Shares sold: 36,500; Proceeds: ~$82,490
- Post-transaction holdings: Not stated in the information provided in this summary (not included in supplied details)
- Notable footnote: Sale executed pursuant to a Rule 10b5-1 trading plan adopted by Oliveto on September 30, 2025. The filer offers to provide a breakdown of the number of shares sold at each specific price in the $2.25–$2.28 range upon request.
Context
This was a sale (code S). Sales executed under pre-established 10b5-1 plans are typically pre-planned and do not, by themselves, indicate a change in the insider’s view of the company. Retail investors may view purchases as stronger signals than routine sales, but this report is factual disclosure of the transaction only.
Insider Transaction Report
- Sale
Common Shares
[F1][F2]2026-04-16$2.26/sh−36,500$82,490→ 446,244 total
Footnotes (2)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote.